AYTU a well-written article: "First to inspire, the aggregate sum of the markets targeted by AYTU’s two therapeutics Natesto® and ZolpiMist™ are estimated to be worth a combined $3.6BN ($1.8BN each for TRT and sleep), and the unique advantages of AYTU’s products create a clear opportunity for the company to grab a huge portion of this market opportunity".